BetterLife Pharma Inc. (CSE: BETR) announced on November 5, 2026, that it has appointed Henry Chow, CPA, CA, as a new director, effective immediately, while long-serving board member Ralph Anthony Pullen has resigned from the board effective November 4, 2026, and will remain with the company as an advisor. Chow brings more than 25 years of public company audit experience, including expertise in U.S. GAAP and SOX 404 internal controls — credentials the company highlighted as it prepares for its next stage of growth. Investors may be watching how this governance strengthening supports BetterLife's ongoing development of BETR-001 for chronic cluster headache and chronic migraine.

Key Points

  • BetterLife Pharma Inc. (CSE: BETR | OTCQB: BETRF | FSE: NPAU) made the board change announcement on November 5, 2026.
  • Henry Chow, CPA, CA, appointed as director; Tony Pullen resigned from the board and transitions to an advisory role.
  • Chow will stand for formal election at the company's annual general and special meeting of shareholders on December 9, 2026.
  • Investors should watch how Chow's U.S. reporting and governance expertise aligns with BetterLife's corporate development objectives.

Henry Chow's Audit and Public Company Credentials

Henry Chow is the founding partner of Saturna Group Chartered Professional Accountants LLP, a Vancouver-based firm he established in 2008 that serves approximately 70 public company audit clients and is registered with the Canadian Public Accountability Board. He began his career articling with KPMG LLP in Vancouver in 2000 before becoming a manager at Manning Elliott LLP in 2005. Chow holds a Bachelor of Commerce (Honours, Accounting) from the University of British Columbia and has been a member of Chartered Professional Accountants of British Columbia since 2003. He has previously served as CFO and/or director of three Canadian-listed public companies.

Tony Pullen's Departure and Continued Advisory Role

Tony Pullen, founder of Lumira Capital, brought decades of life sciences investment experience to BetterLife's board and supported the company through its transition to a focused neurology developer. His resignation is effective November 4, 2026, though the company confirmed he will remain closely involved as an advisor. CEO Ahmad Doroudian acknowledged Pullen's contributions, noting his backing of the company when it was significantly smaller. Pullen stated he looks forward to continuing to support the team in his new advisory capacity, suggesting the relationship between Pullen and BetterLife remains collaborative.

Governance Strengthening Ahead of BetterLife's Growth Phase

Executive Chairman Doug Drysdale described Chow's appointment as an enhancement to BetterLife's governance as the company prepares for its next stage of growth, specifically referencing the reporting and internal control standards required of a U.S.-listed company. BetterLife is developing BETR-001, a non-hallucinogenic derivative of 2-bromo-lysergic acid diethylamide for the preventive treatment of chronic cluster headache and chronic migraine. The company holds a granted U.S. composition-of-matter patent covering BETR-001, which remains an investigational product not yet approved by any regulatory authority.